Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication

Author:

Leung Wai K.1ORCID,Cheung Ka Shing1,Li Bofei2ORCID,Law Simon Y. K.2,Lui Thomas K. L.1

Affiliation:

1. Department of Medicine University of Hong Kong Hong Kong China

2. Department of Surgery University of Hong Kong Hong Kong China

Abstract

SummaryBackgroundThe risk of gastric cancer after Helicobacter pylori (H. pylori) eradication remains unknown.AimTo evaluate the performances of seven different machine learning models in predicting gastric cancer risk after H. pylori eradication.MethodsWe identified H. pylori‐infected patients who had received clarithromycin‐based triple therapy between 2003 and 2014 in Hong Kong. Patients were divided into training (n = 64 238) and validation sets (n = 25 330), according to period of eradication therapy. The data were used to construct seven machine learning models to predict risk of gastric cancer development within 5 years after H. pylori eradication. A total of 26 clinical variables were input into these models. The performances were measured by the area under receiver operating characteristic curve (AUC) analysis.ResultsDuring a mean follow‐up of 4.7 years, 0.21% of H. pylori‐eradicated patients developed gastric cancer. Of the seven machine learning models, extreme gradient boosting (XGBoost) had the best performance in predicting cancer development (AUC 0.97, 95%CI 0.96‐0.98), and was superior to conventional logistic regression (AUC 0.90, 95% CI 0.84‐0.92). With the XGBoost model, the number of patients considered at high risk of gastric cancer was 6.6%, with miss rate of 1.9%. Patient age, presence of intestinal metaplasia, and gastric ulcer were the heavily weighted factors used by the XGBoost.ConclusionBased on simple baseline patient information, machine learning model can accurately predict the risk of post‐eradication gastric cancer. This model could substantially reduce the number of patients who require endoscopic surveillance.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3